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The transformation of a bleeding disorder into a prothrombotic
one is an extraordinary event in blood coagulation. This is what
occurred recently with the description of 3 dysprothrombine-
mias, prothrombin Yukuhashi, prothrombin Belgrade, and pro-
thrombin Padua 2 which do not cause bleeding but, instead,
show antithrombin resistance with consequent thrombosis.1-4 It
is now of paramount importance to verify if the Arg596 muta-
tions are the only ones responsible for the shift from a hemor-
rhagic condition to a thrombophilic one or if other amino acids
of the same area of the prothrombin molecule encoded by exon
14 might also be associated with the change.
Two approaches are available, namely (1) the restudy of
cases of prothrombin defect with mutations encoded around
the Arg596 residue and (2) chimeric studies in vitro. The
3 prothrombin defects close to the Arg596 residue are
prothrombin Scranton (Lys399Thr) downstream and pro-
thrombin Perija (Gly591Ala) and prothrombin Saint Denis
(Asp395Glu), upstream.5-8
The relation with prothrombin Scranton is interesting. This
family had a Lys599Thr mutation, the patients were all hetero-
zygotes and also neither a bleeding tendency nor thrombosis,
namely, probably, no antithrombin resistance.5
Prothrombin Perija (Gly591Ala) is upstream to Arg596. The
patient is homozygote for the defect and shows a mild bleeding
tendency despite a prothrombin level of 2% of normal but no
thrombosis.6,7 Prothrombin Saint Denis (Asp595Glu) has no
bleeding and no thrombosis and is also upstream (Figure 1).8
Mutation involving amino acids: 592, 593, and 594 of the
prothrombin molecule, upstream to the Arg596, unfortunately,
have not been yet demonstrated in patients. The same is true for
the amino acids 597 and 598, downstream of Arg596.9,10
However, chimeric studies in vitro have shown that the
Glu592Gln mutation causes antithrombin resistance.11
The mutations seen in the dysprothrombinemias associated
with venous thrombosis are Arg596Leu, Arg596Gln, and
Arg596Trp. These mutations confer to the prothrombin mole-
cule a resistance to antithrombin. This indicates that the
Arg596 is crucial since the antithrombin resistance occurs
regardless of the replacing amino acid Leu, Gln, or Trp. It is
worth noting that a delayed or defective binding to antithrom-
bin had been suspected to exist also for prothrombin Perija
(Arg591Ala) and prothrombin Saint Denis (Asp595Glu). How-
ever, since the carriers of these mutation showed no thrombotic
event, the finding was not pursued.7,8
It would be interesting to know if the patient with prothrom-
bin Saint Denis (Asp595Glu) which is a mutation attached to
Arg596 has ever developed thrombosis. Since the patient was
reported as a new born and followed for only about 2.5 years
(30 months), the occurrence of a thrombotic event could not be
excluded.8 Unfortunately, no further information is available.
The mean age for the occurrence of thrombosis, for all the
Arg596mutated patients, excluding prothrombin Amrita
another case of Arg596Gln mutation seen in India,12 is about
20 years.
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Chimeric studies in vitro have shown that mutation
Lys599Arg and mutation Glu592Gln show antithrombin
resistance similar to that seen in prothrombin Yukuhashi
(Arg596Leu) and prothrombin Belgrade (Arg596Gln).9 A
mutation similar to Lys599Arg has been found, clinically,
in prothrombin Scranton (Lys599Thr), whereas the other
mutation (Glu592Gln) so far has no clinical counterpart or
confirmation.
Granting the differences that may be present between chi-
meric in vitro studies and clinical observations, it would seem
that the substitution of amino acid Lys599 either with Arg
(chimeric studies) or with Thr (Prothrombin Scranton) may
cause resistance to antithrombin.5,9 However, antithrombin
resistance has not been searched for in the original paper deal-
ing with in prothrombin Scranton.5
These clinical observations and chimeric studies, taken all
together, would seem to indicate that the area of prothrombin
encoded by exon 14, from Gly591 to Lys599 are associated
with impaired or delayed binding to antithrombin and to antith-
rombin resistance. It is not clear yet whether such features
extend to amino acids downstream from Arg596, for example,
to prothrombin Scranton (Lys599Thr).
It seems therefore that the area of prothrombin associated
with antithrombin resistance spans at least from residue Gly591
(prothrombin Perija) to residue Lys599 (prothrombin Scran-
ton), regardless of the amino acid substitution. Since only
patients with the Arg substitutions with Leu, Gln, or Trp are
associated with venous thrombosis, it would seem that the lack
of Arg, regardless of the substitution, Leu, Gln, or Trp, is
responsible for the occurrence of the antithrombin resistance.
Alternatively, it could be that these abnormal prothrombins
Arg596Leu, Arg596Gln, or Arg596Trp could be the cause of
the appearance of antithrombin resistance.
This seem very unlikely because of the great structural dif-
ferences existing among leucine, glutamine, and tryptophan.
Defects in the amino acid 592, 593, 594, and 597, 598 have
not been reported yet in patients.10,11
The discovery of these patients could be useful in defining
the area of the prothrombin molecule encoded by exon 14
associated with antithrombin resistance and the appearance
of thrombosis.
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Figure 1. Schematic representation of the main features of the dysprothrombinemias due to Arg596 substitution and of other close
dysprothrombinemias, all encoded by exon 14. The probable decreased binding to antithrombin for prothrombin Scranton is inferred from
chimeric in vitro studies. A.A. indicates amino acid; AT, antithrombin; tromb, thrombosis.
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